We are live on ! Find out more
OCA

Octagon Capital Advisors Portfolio holdings

AUM $904M
1-Year Est. Return 737.04%
This Fund
S&P 500
This Quarter Est. Return
-4.48%
1 Year Est. Return
+737.04%
3 Year Est. Return
+2,554.78%
5 Year Est. Return
+4,333.84%
10 Year Est. Return
–
AUM
$265M
AUM Growth
-$23M
Cap. Flow
-$923K
Cap. Flow %
-0.35%
Top 10 Hldgs %
61.75%
Holding
38
New
7
Increased
6
Reduced
4
Closed
10

Top Buys

Rank Stock Value
1
IMA
ImageneBio Inc
IMA
+$11.4M
2
DSGN icon
Design Therapeutics
DSGN
+$8.43M
3
CNTB
Connect Biopharma Holdings
CNTB
+$6.36M
4
MRUS
Merus
MRUS
+$4.62M
5
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$4.13M

Top Sells

Rank Stock Value
1
CLDX icon
Celldex Therapeutics
CLDX
+$11M
2
CALT
Calliditas Therapeutics AB American Depositary Shares
CALT
+$6.72M
3
KYNB
Kyntra Bio
KYNB
+$5.42M
4
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$5.22M
5
KURA icon
Kura Oncology
KURA
+$4.9M

Sector Composition

Rank Sector Weight
1 Healthcare 95.99%
2 Financials 1.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBP
1
NovaBridge Biosciences American Depositary Shares
NBP
$205M
$25.7M 9.68%
530,050
+75,500
+17% +$4.1M
CRIS icon
2
Curis
CRIS
$9.53M
$24.1M 9.08%
5,321
-179
-3% -$749K
APLS
3
DELISTED
Apellis Pharmaceuticals
APLS
$23.5M 8.86%
548,374
– –
FDMT icon
4
4D Molecular Therapeutics
FDMT
$526M
$16.4M 6.18%
378,288
+511
+0.1% +$22.6K
XLRN
5
DELISTED
Acceleron Pharma
XLRN
$15.2M 5.74%
112,363
– –
GOSS icon
6
Gossamer Bio
GOSS
$66.5M
$13.1M 4.92%
1,413,138
-150,000
-10% -$1.51M
ARVN icon
7
Arvinas
ARVN
$518M
$11.8M 4.44%
178,500
– –
CLDX icon
8
Celldex Therapeutics
CLDX
$2.77B
$11.6M 4.36%
561,398
-480,000
-46% -$11M
IMA
9
ImageneBio Inc
IMA
$63.1M
$11.3M 4.26%
+33,333
New +$11.4M
RCUS icon
10
Arcus Biosciences
RCUS
$3.57B
$11.2M 4.23%
400,000
+100,000
+33% +$3.48M
RNAM
11
DELISTED
Avidity Biosciences
RNAM
$9.74M 3.67%
446,641
+16,600
+4% +$406K
DYN icon
12
Dyne Therapeutics
DYN
$4.04B
$9.06M 3.41%
583,649
+102,111
+21% +$1.98M
PMVP icon
13
PMV Pharmaceuticals
PMVP
$66.1M
$8.22M 3.1%
250,000
– –
CCXI
14
DELISTED
ChemoCentryx, Inc.
CCXI
$7.69M 2.9%
150,076
-75,000
-33% -$4.51M
DSGN icon
15
Design Therapeutics
DSGN
$736M
$7.47M 2.82%
+250,000
New +$8.43M
CNTB
16
Connect Biopharma Holdings
CNTB
$135M
$6.91M 2.6%
+373,492
New +$6.36M
TSHA icon
17
Taysha Gene Therapies
TSHA
$1.59B
$6.5M 2.45%
320,440
– –
CRDF icon
18
Cardiff Oncology
CRDF
$64.3M
$6.02M 2.27%
650,000
– –
NGM
19
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$5.81M 2.19%
200,000
+124,773
+166% +$3.49M
RVMD icon
20
Revolution Medicines
RVMD
$40.2B
$5.79M 2.18%
126,136
– –
KRON
21
DELISTED
Kronos Bio
KRON
$4.28M 1.61%
146,173
– –
ISEE
22
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$4.2M 1.58%
680,036
– –
MRUS
23
DELISTED
Merus
MRUS
$4.18M 1.57%
+200,000
New +$4.62M
MLTX icon
24
MoonLake Immunotherapeutics
MLTX
$1.59B
$4.08M 1.54%
400,000
– –
EWTX icon
25
Edgewise Therapeutics
EWTX
$4.39B
$4.06M 1.53%
+125,000
New +$4.05M
1
2

Similar funds

AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
AOWM
Asset One Wealth Management Bellevue, Washington $904M AUM
SWM
Sendero Wealth Management San Antonio, Texas $904M AUM 22.78% 1-Year Est. Return
EI
EnCap Investments Houston, Texas $905M AUM
PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
PSCM
Per Stirling Capital Management Austin, Texas $905M AUM 17.06% 1-Year Est. Return
EWM
Evermay Wealth Management Arlington, Virginia $902M AUM 14.76% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Octagon Capital Advisors's Q1 2021 Portfolio in Review

As of Q1 2021, Octagon Capital Advisors held 38 positions worth $265M, down 8% from $288M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Octagon Capital Advisors's Q1 2021 filing shows 7 new, 6 increased, 4 reduced and 10 closed positions. Its largest new stake was ImageneBio Inc: 33,333 shares worth $11.3M. The largest sale was Celldex Therapeutics, an estimated $11M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Financials.

  • Octagon Capital Advisors's largest Q1 2021 buy was ImageneBio Inc: 33,333 shares worth $11.3M.
  • Octagon Capital Advisors added most to NovaBridge Biosciences American Depositary Shares in Q1 2021, an estimated $4.1M increase.
  • Octagon Capital Advisors's biggest Q1 2021 reduction was Celldex Therapeutics, cutting an estimated $11M.
  • Octagon Capital Advisors fully exited Calliditas Therapeutics AB American Depositary Shares in Q1 2021, selling an estimated $6.72M.
  • Octagon Capital Advisors's ten largest holdings make up 62% of its $265M portfolio in Q1 2021.
  • Octagon Capital Advisors opened 7 new positions and closed 10 in Q1 2021.
  • Octagon Capital Advisors's portfolio value fell 8% quarter-over-quarter to $265M.

Based on Octagon Capital Advisors's 13F filing for Q1 2021, filed 17 May 2021.